INTRODUCTION

Dipeptidyl peptidase-4 (DPP-4) inhibitors
improve glycemic control in patients with type 2 diabetes mellitus (T2DM) by increasing circulating levels of incretins, endogenous gutderived peptide hormones that enhance insulin secretion and suppress glucagon release in a glucose-dependent manner [1] [2] [3] [4] . Several DPP-4 inhibitors are widely approved for use as oral antihyperglycemic agents in treating patients with T2DM. All have been shown to provide significant improvements in standard indices of glycemic control [5] . There may be important differences between them, however, in the extent to which they provide sustained pharmacodynamic (PD) action (DPP-4 inhibition) throughout their recommended dosing cycles. The existing PD data on these agents have come from separate studies in which each agent was evaluated individually, with different study populations and dosing regimens (single versus multiple dose administration) [6] [7] [8] [9] [10] [11] . There is a need, therefore, for comparison of levels of DPP-4 inhibition between different agents within a single study in which conditions are standardized. There also is a need to minimize the impact of dilution and substrate competition artifacts that may be introduced in the process of assaying DPP-4 inhibition ex vivo [9, [11] [12] [13] [14] and prevent meaningful comparison between agents even when tested in parallel within the same study. Reagent solutions must be added to plasma in order to assay DPP-4 activity. As a result, plasma drug concentrations will be lower in an ex vivo assay than they are in vivo and this dilution effect may lead to underestimation of levels of DPP-4 inhibition. The impact of this effect will vary depending on the rate at which a DPP-4 inhibitor dissociates from its binding site on the enzyme, the amount of plasma dilution, and the length of time between the addition of reagents and the measurement of enzyme activity. In addition, there is the potential for ex vivo underestimation of DPP-4 inhibition due to substrate competition. If inhibition is assessed with substrate present at a level that saturates the enzyme, then competitive DPP-4
inhibitors are likely to appear to be less effective than they are under physiological conditions in vivo, where endogenous substrates are likely to be present at subsaturating concentrations.
Measurement of DPP-4 inhibition by
sitagliptin is expected to be especially sensitive to these two artifacts because binding between sitagliptin and DPP-4 is competitive and rapidly reversible. When plasma containing sitagliptin is diluted, the half-life (t 1/2 ) for readjustment to the new equilibrium for DPP-4 binding is \2 min [14] , an interval that is brief compared with the length of time over which assays of plasma DPP-4
are typically run. Measurements of DPP-4 inhibition by vildagliptin may also be sensitive to the dilution artifact because the t 1/2 for dissociation of vildagliptin from DPP-4 is in the order of 3.5 min [14] . Measurements of DPP-4
inhibition by saxagliptin and an active metabolite, 5-hydroxy-saxagliptin, are likely to be relatively insensitive to this dilution effect because these molecular species dissociate slowly from DPP-4, with t 1/2 values of 50 and 23 min, respectively [14] . Given these differences in binding kinetics, it follows that valid comparisons between these agents can only be made when DPP-4 inhibition is measured using an assay condition that minimizes the impact of plasma dilution. In the present study, we have directly compared profiles of DPP-4 inhibition over time in patients with T2DM treated with saxagliptin, sitagliptin, and vildagliptin using an assay in which plasma was diluted by only 11%, a level that is likely to have only a minimal effect on outcome, regardless of binding kinetics.
Using a randomized, placebo-controlled, openlabel, crossover design, patients in a single cohort were treated in successive study periods for 5 days (so that all agents could reach steadystate conditions) with the highest recommended doses for each agent. Pharmacokinetic (PK) and DPP-4 inhibition data were obtained at various times throughout these treatments and for an additional 4 days after the last doses were given.
The prespecified primary endpoint was the 'trough' level of DPP-4 inhibition measured after patients received their final doses in each study period. It was assessed at 24 h postdose in subjects being treated with study drugs q.d. and 
METHODS
This study was performed in accordance with all local laws and regulations, The assay solutions were incubated at 37°C 
Statistical Methods
All available data were included in the analysis (including data from patients who did not complete the study but had at least one measurement). Levels of DPP-4 inhibition were analyzed using a linear mixed-effects model with fixed-effects terms for treatment and period. Data were transformed to a log-percent scale for analysis and then back-transformed to a linear scale for reporting. Baseline was defined in each period as the predose value on Day 1.
Inference testing was one-sided and significance was defined as p\0.05. Roger's method [16] 
RESULTS
The randomized cohort included 12 women and 10 men (all Caucasian) with a mean (range) age of 55 (43-64) years and body mass index of 32 (26-39) kg/m 2 . Mean (range) baseline HbA 1C was 7.4% (6.4-9.0%).
Five patients discontinued prior to study completion. One withdrew consent, one was determined after randomization not to have met eligibility criteria, and three patients had elevated blood glucose concentrations that met the prespecified criteria for discontinuation.
These incidents of elevated blood glucose occurred primarily prior to dosing with active treatments (i.e., during washout periods). The investigator did not consider these to be adverse events (AEs).
Predose levels of DPP-4 activity (A 0 ) were 3.70-6.36 RFU/s (10.1-to 17.4-fold greater than the LOQ). Thus, the upper limits for quantitation of DPP-4 inhibition in individual measurements were between 90% and 94%.
Actual values varied for each subject and treatment period based on the baseline DPP-4 activity measured in that period.
Plasma DPP-4 Inhibition
Trough levels of DPP-4 inhibition were generally stable by the morning of Day 3 during all active treatments (Fig. 1a) and each of these provided nearly maximal inhibition of DPP-4 at 12 h postdose as assessed on Day 5 (Fig. 1b) . Two of the treatments, sitagliptin and vildagliptin b.i.d., provided nearly maximal inhibition at 24 h postdose as determined predose on Days 1-5 and also on the morning of Day 6, when the primary endpoint was assessed. With these treatments, LS-mean trough DPP-4 inhibition on Day 6 was 91.7% and 90.6%, respectively ( 
Pharmacokinetic Observations
Observed values for AUC 0-24 h , maximal concentration (C max ), concentration at 24 h (C 24 h ), and other PK parameters are shown in 
Safety
The study treatments were generally well tolerated. In total, 10 AEs were reported in 7 of the 22 patients enrolled. Headache was the most commonly reported AE (six events reported in three patients). Five AEs were considered to be study related. These included four events of headache (two that were attributed to saxagliptin treatment and two that were attributed to sitagliptin treatment) and one event of influenza that was attributed to saxagliptin treatment. All AEs were reported to be mild (n = 6) or moderate (n = 4) in intensity and transient in nature. There were no deaths, no serious AEs, and no AEs that led to withdrawal from the study.
Other Observations
In any period in which a patient was administered placebo, plasma concentrations of saxagliptin, 5-hydroxy-saxagliptin, sitagliptin, in which single doses of 50 and 100 mg vildagliptin were given to patients with T2DM, the levels of DPP-4 inhibition observed at 24 h postdose were approximately 14% and 35%, respectively [7] . In the present study, the mean (±standard error) level of DPP-4 inhibition 24 h after the first dose of vildagliptin 50 mg q.d. was 9.1 ± 5.0% (Fig. 1 ). This value is reasonably consistent with the prior result.
In the present study, sitagliptin provided a greater trough level of DPP-4 inhibition than was previously observed in a Phase I trial in which patients with T2DM were administered a single dose of 200 mg sitagliptin. In that study, plasma samples were diluted 2.5-fold prior to ex vivo assay and the level of DPP-4 inhibition measured at 24 h postdose was 80.1% [6] . The greater level of DPP-4 inhibition observed in the present study could be accounted for by the difference in plasma dilution. A statistical method has been described to correct for this dilution, and based on this method one would expect to observe 80% DPP-4 inhibition by sitagliptin after 2.5-fold dilution of plasma when the true level of inhibition in vivo is *96% [9] . We have not applied this correction in the present analysis because the extent of plasma dilution in our assay was sufficiently small (11%) that its effect could reasonably be regarded as negligible.
The PK findings in the present study were generally consistent with those reported Hence, differences in drug exposure did not appear to play a role in the observed differences in PD effect.
One limitation of this study was that antihyperglycemic efficacy was not evaluated.
Hence, uncertainty remains as to whether the observed differences in DPP-4 inhibition have meaningful implications for glycemic efficacy.
However, a recent, model-based meta-analysis of published data found evidence for greater reductions in HbA 1C with more sustained DPP-4 inhibition [18] . Increasing reductions in HbA 1C were found in this meta-analysis even as the weighted average DPP-4 inhibition increased beyond 90%, supporting the concept that maintaining nearly complete inhibition of DPP-4 over entire dosing cycles may be important in order to maximize antihyperglycemic efficacy with this class of drugs. In addition, we note that the finding of similar DPP-4 inhibition during treatment in our comparison of once-daily sitagliptin with twicedaily vildagliptin is consistent with prior reports suggesting generally similar glycemic efficacy when these regimens are compared [19] .
In a study comparing the efficacy of sitagliptin 100 mg q.d. with saxagliptin 5 mg q.d. as an addon to metformin for 18 weeks, the adjusted mean change from baseline in HbA 1C was -0.62% versus -0.52% for sitagliptin and saxagliptin, respectively [20] . Although this difference was within the study's prespecified limit for noninferiority for HbA 1C , the sitagliptin group had a numerically greater adjusted mean change 
